Rossana Carter, MD
Internal Medicine · Macon, GANPI 1912089251
Payments from drug & device makers
Across 314 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$741
- AbbVie$661
- Amgen$558
- Pfizer$516
- AstraZeneca$477
- Lilly USA, LLC$284
- plus $2K from 36 others
What the payments were for
- Food & beverage$5,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $741 |
| AbbVie(2 entities) | 34 | $661 |
| Amgen | 35 | $558 |
| Pfizer | 28 | $516 |
| AstraZeneca | 29 | $477 |
| Lilly USA, LLC | 18 | $284 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $240 |
| Amarin Pharma, Inc. | 13 | $229 |
| Boehringer Ingelheim | 10 | $185 |
| Astellas Pharma US Inc | 7 | $144 |
| Esperion Therapeutics, Inc. | 7 | $130 |
| Biohaven Pharmaceuticals, Inc. | 8 | $128 |
| Bayer | 4 | $86 |
| GSK | 6 | $85 |
| Merck | 5 | $78 |
| Idorsia Pharmaceuticals US Inc | 5 | $73 |
| Dexcom, Inc. | 4 | $73 |
| Corcept Therapeutics | 3 | $72 |
| Radius Health, Inc. | 3 | $57 |
| Seqirus USA Inc | 3 | $50 |
| Ardelyx, Inc. | 3 | $50 |
| Novartis | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Abbott | 2 | $37 |
| Medtronic | 1 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Kerecis Limited | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Vertex | 1 | $25 |
| Bausch Health US, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Exact Sciences | 1 | $13 |
How this compares
$5,444 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $64,364 |
| MounjaroTirzepatide | 45 | $49,326 |
| JardianceEmpagliflozin | 20 | $30,964 |
| EliquisApixaban | 43 | $29,134 |
| FarxigaDapagliflozin Propanediol | 26 | $17,005 |
| MyrbetriqMirabegron | 14 | $16,402 |
| Repatha SureclickEvolocumab | 17 | $15,595 |
| TrulicityDulaglutide | 13 | $13,142 |
| LinzessLinaclotide | 11 | $9,027 |
| LivaloPitavastatin Calcium | 11 | $8,600 |
| JanuviaSitagliptin Phosphate | 14 | $8,262 |
| SynthroidLevothyroxine Sodium | 103 | $7,020 |
| Pitavastatin Calcium | 18 | $6,022 |
| Levothyroxine Sodium | 406 | $4,175 |
| Pravastatin Sodium | 250 | $4,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $741 | $64,36453 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $62,46958 claims |
| Boehringer IngelheimJardiance | $185 | $30,96420 claims |
| PfizerEliquis | $516 | $29,13443 claims |
| AstraZenecaFarxiga | $477 | $17,00526 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $16,40214 claims |
| AbbVieLinzess, Synthroid | $661 | $16,047114 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $33 | $8,60011 claims |
| MerckJanuvia | $78 | $8,26214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,175406 claims |
| Eisai Inc.Dayvigo | $39 | $2,71914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Macon
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.